Klára Szondy

2.8k total citations · 1 hit paper
11 papers, 2.1k citations indexed

About

Klára Szondy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Klára Szondy has authored 11 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Klára Szondy's work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Klára Szondy is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Klára Szondy collaborates with scholars based in Hungary, Canada and United States. Klára Szondy's co-authors include Christopher E. Desch, Shaharyar, Filippo de Marinis, Christian Manegold, Nasser H. Hanna, Radj Gervais, Joachim von Pawel, Thomas Müller, Lawrence Einhorn and Paul A. Bunn and has published in prestigious journals such as Journal of Clinical Oncology, European Respiratory Journal and Journal of Molecular Diagnostics.

In The Last Decade

Klára Szondy

11 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Nasser H. Hanna, Frances A. Shepherd et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Klára Szondy Hungary	6	1.8k	1.6k	372	204	104	11	2.1k
Shaharyar Canada	5	1.7k 1.0×	1.5k 1.0×	347 0.9×	210 1.0×	105 1.0×	6	2.0k
Cesare Gridelli Italy	18	2.4k 1.3×	2.1k 1.4×	527 1.4×	270 1.3×	179 1.7×	37	2.9k
José Barrueco United States	17	1.1k 0.6×	1.3k 0.9×	465 1.3×	181 0.9×	127 1.2×	36	2.0k
Laurent Gressot United States	6	1.6k 0.9×	1.5k 1.0×	310 0.8×	167 0.8×	90 0.9×	7	1.8k
Nadia Chouaki France	19	1.3k 0.8×	1.3k 0.8×	226 0.6×	210 1.0×	200 1.9×	48	1.7k
Patrick Peterson United States	21	2.2k 1.2×	1.8k 1.2×	472 1.3×	310 1.5×	166 1.6×	55	2.6k
Jin Seok Ahn South Korea	25	1.9k 1.1×	1.5k 1.0×	414 1.1×	299 1.5×	145 1.4×	56	2.2k
Daniel T. Milton United States	16	1.9k 1.1×	1.6k 1.0×	587 1.6×	383 1.9×	125 1.2×	27	2.4k
Purvish Parikh India	9	2.1k 1.2×	1.8k 1.1×	521 1.4×	412 2.0×	186 1.8×	21	2.6k
Symantha Melemed United States	12	1.2k 0.7×	990 0.6×	236 0.6×	190 0.9×	123 1.2×	16	1.4k

Countries citing papers authored by Klára Szondy

Since Specialization

Citations

This map shows the geographic impact of Klára Szondy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klára Szondy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klára Szondy more than expected).

Fields of papers citing papers by Klára Szondy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klára Szondy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klára Szondy. The network helps show where Klára Szondy may publish in the future.

Co-authorship network of co-authors of Klára Szondy

This figure shows the co-authorship network connecting the top 25 collaborators of Klára Szondy. A scholar is included among the top collaborators of Klára Szondy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klára Szondy. Klára Szondy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Hanna, Nasser H., Frances A. Shepherd, Frank V. Fossella, et al.. (2023). Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. Journal of Clinical Oncology. 41(15). 2682–2690. 8 indexed citations

Horváth, Ákos G., P.J. van der Wolf, János Nagy, et al.. (2015). OVERVIEW OF A DIGITAL TOMOSYNTHESIS DEVELOPMENT: NEW APPROACHES FOR LOW-DOSE CHEST IMAGING. Radiation Protection Dosimetry. 169(1-4). 171–176. 5 indexed citations

Szondy, Klára, Krisztina Rusai, Attila J. Szabó, et al.. (2012). Tumor Cell Expression of Heat Shock Protein (HSP) 72 is Influenced by HSP72 [HSPA1B A(1267)G] Polymorphism and Predicts Survival in Small Cell Lung Cancer (SCLC) Patients. Cancer Investigation. 30(4). 317–322. 10 indexed citations

Máthé, Csaba, Anikó Bohács, Zsolt István Komlósi, et al.. (2010). Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. European Respiratory Journal. 37(4). 888–894. 44 indexed citations

Losonczy, György, Csaba Máthé, Veronika Müller, Klára Szondy, & Judit Moldvay. (2010). A cisplatin okozta nefrotoxicitás előfordulása, kockázati tényezői és megelőzése tüdőkarcinómás betegekben. PubMed. 54(4). 289–296. 5 indexed citations

Pápay, Judit, Zoltàn Sápi, Edit Szabó, et al.. (2008). Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry. Journal of Molecular Diagnostics. 10(2). 160–168. 49 indexed citations

Ostoros, Gyula, et al.. (2006). Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme.. PubMed. 25(6C). 4759–62. 3 indexed citations

Ostoros, Gyula, Gábor G. Kovács, Klára Szondy, & Balázs Döme. (2005). [New therapies for non-small cell lung cancer].. PubMed. 146(21). 1135–41. 1 indexed citations

Ostoros, Gyula, et al.. (2005). Efficacy of gemcitabine--cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer.. PubMed. 25(1B). 471–5. 6 indexed citations

10.

Hanna, Nasser H., Frances A. Shepherd, Frank V. Fossella, et al.. (2004). Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy. Journal of Clinical Oncology. 22(9). 1589–1597. 1924 indexed citations breakdown →

11.

Manegold, C., R. Gervais, K Aigner, et al.. (2003). 57 Pemetrexed vs docetaxel: a phase III study in patients with advanced non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. European Journal of Cancer Supplements. 1(5). S22–S22. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact